Clinical Trials Logo
  1. Home
  2. Coronary Artery Bypass Grafting
  3. NCT01528514
  4. Details
NCT01528514 Clinical Trial

Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

Coronary Artery Bypass Grafting Clinical Trial

— CUPID  

Official title:
The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01528514
Other study ID # MRG5380258
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2009
Est. completion date December 2012

Study information
Verified date September 2019
Source Thailand Research Fund
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Recruitment information / eligibility
Status Completed
Enrollment 200
Est. completion date December 2012
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

Patients undergoing CABG without valve surgery

Exclusion Criteria:

- emergency cardiac surgery

- any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization

- patients with cholestatic jaundice (total bilirubin > 2-fold ULN)

- severe liver disease (AST or ALT > 3-fold ULN)

Study Design

Related Conditions & MeSH terms

Intervention

Dietary Supplement:
• Curcuminoids
Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
Other:
• Placebo
Placebo in capsule form, 4 capsules 4 times/day

Locations
Country Name City State
Thailand Maharaj Nakorn Chiang Mai hospital Chiang Mai

Sponsors (1)
Lead Sponsor Collaborator
Wanwarang Wongcharoen, MD.

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of postoperative myocardial infarction participants will be followed for the duration of hospital stay, an expected average of 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT01850082 - Randomized Endo-Vein Graft Prospective N/A
Not yet recruiting NCT04657835 - Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery. N/A
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01378221 - VItamin D Metabolism in SEnescent Cardiac Surgery Patients N/A
Completed NCT00848796 - Comparative Study of Two Brands of Heparin Already on the Market N/A
Not yet recruiting NCT05552586 - Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery N/A
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Completed NCT00420667 - Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery N/A
Recruiting NCT04197700 - The PRESSURE CABG Cardiac Surgery Trial N/A
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Not yet recruiting NCT06326996 - Thiamine Intervention and Coronary Artery Bypass Grafting N/A
Not yet recruiting NCT02732574 - Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery N/A
Completed NCT00903604 - Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2
Completed NCT01182688 - Prospective Review of Procalcitonin After Cardiac Surgery N/A
Completed NCT02737215 - Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Recruiting NCT05441358 - Assessment of Platelet Function in Patients Undergoing Open Heart Surgery
Recruiting NCT02400125 - China Cardiovascular Surgery Registry N/A
Terminated NCT00628264 - Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2